The Clinical Trial Accessibility Checklist: How Does Your Organization Measure Up?

7 Actions Biopharma Can Take To Create A More Accessible Environment For Clinical Trial Participants

This year marks the 30th anniversary of the NIH revitalization act that required women and minorities to be included in clinical research in the US. Putting that into perspective, we have only really been collecting data at scale on women and minorities since the movie Jurassic Park was launched. If we want more people to participate in clinical trials, it is time to get real about reducing the burden of research on volunteers.

Number seven
• Source: Shutterstock

Clinical trials are not designed to help the study participants. They are designed to gather data to develop new treatments for people in the future. The biopharma industry depends on volunteers to participate in clinical trials that are not designed to help them. It is how we advance science and get new treatments to the world. Yet our industry is not doing enough to reduce the burden on volunteers in clinical trials.

Here are seven pragmatic actions the biopharma sector can take today to create a more accessible environment for clinical trial participants.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Diversity & Inclusion

RESILIENCE Initiative Navigates The World Of Making Medicines Through VR Technology

 

The process of manufacturing medicines can often be complex, expensive and harmful to the environment. Initiatives like RESILIENCE UK are seeking to simplify this process, utilizing VR technology to create a more sustainable learning environment for both students and companies.

Cracking Through ‘The Bamboo Ceiling’: East Asians Reach For Pharma Leadership

 
• By 

Despite the significant presence of East Asian professionals in the pharmaceutical industry, their representation in top leadership roles remains disproportionately low. This disparity can be attributed to cultural bias, limited access to influential networks, and systemic barriers within corporate structures.

Infographic: Analyzing The Gap In Women’s Health Care

 

Looking at a recent McKinsey report alongside our Evaluate data, the below infographic provides insight into the investment scene of pharma and raises questions as to how the industry is seemingly yet to seize the opportunity in women's health.

Growing Calls For Labelling Changes With Obesity Patients In Mind

 
• By 

Despite significant investments in weight loss treatments, pharmaceutical companies face criticism for neglecting to study their drugs in obese patients, possibly leading to incomplete labeling and patient risks, prompting calls for the FDA to enforce more inclusive clinical trials and updated drug information.

More from ESG